EUCTR2008-005817-23-LT进行中（未招募）1 期
A Phase IIA, Multicenter, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-8245 in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 76
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Patient has type 2 diabetes mellitus (T2DM).
- •Patient is = 18 and = 65 years of age on day of signing informed consent.
- •Patient has body mass index (BMI) > 27 kg/m2 and < 43 kg/m2.
- •Patient meets one of the following criteria as indicated by a yes answer to one of the following:
- •1) patient is drug naïve or currently not on AHA (off AHA for = 12 weeks), and has Visit 1 / Screening Visit A1C = 7% and = 10% OR
- •2) patient is currently on single AHA and has Visit 1 / Screening Visit A1C = 7% and = 9.5% OR
- •3) patient is currently on low dose, oral AHA combination therapy (i.e., = 50% maximum labeled dose of each agent) and has a Visit 1 / Screening Visit A1C = 6.5% and = 9.5%
- •NOTE: Patients who at Visit 1 are on PPAR-? agents (i.e., TZDs), either as monotherapy or in combination therapy with other AHA, are not allowed to participate in the study.
- •Patient is a male, or female without reproductive potential. A female patient who is not of reproductive potential is defined as one who has either
- •4) reached natural menopause (defined as = 6 months of spontaneous amenorrhea with serum FSH levels in the postmenopausal range as determined by the central laboratory, or = 2 years of spontaneous amenorrhea in woman > 45 years of age.
- •5) undergone post surgical bilateral oophorectomy and/or hysterectomy,
- •6) undergone a bilateral tubal ligation.
- •Patient has an FPG = 130 mg/dL (7.2 mmol/L) and = 260 mg/dL (14.4 mmol/L).
- •NOTE: If Visit 3 FPG does not meet this criterion AND is not consistent with the patient's recent fasting SBGM values, a single repeat measurement may be performed at the discretion of the Investigator. If the repeat value meets FPG inclusion criterion, patient may continue in the study.
- •Patient has successfully completed the 24-hour domicile procedures which includes consuming = 50% of each meal based on caloric content.
- •NOTE: If the patient does not meet this inclusion criterion and it is the Investigator's opinion that the patient is likely to meet this criterion during a second attempt, the current visit can be changed to an unscheduled visit, and the patient can be rescheduled for Visit 4/Day -1 within one week, and be randomized only if the repeat 24-hour domicile procedures are completed successfully.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •History of type 1 diabetes mellitus or a history of ketoacidosis, or patient is assessed by the investigator as possibly having type 1 diabetes confirmed with a C -peptide < 0.7 ng/mL (< 0.23 nmol/L).
- •Has been treated with PPAR? agent (i.e., TZD [pioglitazone or rosiglitazone]) or with insulin therapy within the past 12 weeks.
- •Has been treated with lipid lowering medications such as statins (i.e., HMG-CoA reductases [e.g., simvastatin, atorvastatin]), fibrates (e.g., gemfibrozil, fenofibrate), ezetimibe, niacin, or bile acid sequestrants within the prior 4 weeks.
- •Has been on a weight loss program and is not in the maintenance phase, or patient started weight loss medication (e.g., orlistat, rimonabant, sibutramine, etc.) within the prior 12 weeks.
- •Is being treated with immunosuppressive or immunomodulating agents (e.g., methotrexate, cyclosporine, etanercept), or patient is on, or is likely to require treatment with pharmacological doses of corticosteroids, or is on physiologic replacement therapy with oral corticosteroids (i.e., patient with adrenal insufficiency).
- •Is currently participating in a study, or has participated in a study with or without an investigational compound or device within the prior 12 weeks of signing informed consent.
- •Has undergone a surgical procedure within 30 days prior to signing informed consent or has planned major surgery.
- •Has a medical history of active liver disease (other than non-alcoholic hepatic steatosis), including chronic active hepatitis B or C (assessed by medical history), cirrhosis, or symptomatic gallbladder disease.
- •Has history of coronary heart disease or congestive heart failure.
- •Had stroke or transient ischemic neurological disorder within the past 6 months.
- •Has severe peripheral vascular disease (e.g., manifested by claudication with minimal activity, a non-healing ischemic ulcer, or disease which is likely to require intervention such as with bypass or angioplasty).
- •Has a systolic blood pressure > 160 mm Hg or diastolic > 90 mm Hg and blood pressure is not considered likely to be under these limits by Visit 3/Week -2 with an adjustment in antihypertensive medication.
- •Has a clinically important hematological disorder (e.g., aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia).
- •Has a history of malignancy = 5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer. Patient with a history of malignancy > 5 years prior to signing informed consent should have no evidence of disease.
- •Has a history of macular edema or vitreous hemorrhage.
- •Has a recent history (i.e., within prior two weeks) of eye infection or another inflammatory condition of the eye or conjunctiva, including uveitis or scleritis.
- •Has a history of contact lens use within the prior 3 months.
- •Has dry eye syndrome, or has any condition that may predispose to dry eye condition (e.g., lupus, rheumatoid arthritis, etc.).
- •Has used medicated eye drops within the prior 4 weeks.
- •Has exclusionary lab values as described in the protocol.
- •Is, at the time of signing informed co
研究者
相似试验
进行中（未招募）
1 期
A Phase IIA, Multicenter, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-8245 in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic ControlMedDRA version: 9.1 Level: LLT Classification code 10045242 Term: Type II diabetes mellitusType 2 Diabetes MellitusEUCTR2008-005817-23-PLMerck & Co., Inc.76
已完成
不适用
A Study to Assess the Safety and Efficacy of MK8245 in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK8245-005 AM2)-E10 Insulin-dependent diabetes mellitus-E14 Unspecified diabetes mellitusInsulin-dependent diabetes mellitusUnspecified diabetes mellitusE10E14PER-159-08MERCK SHARP & DOHME PERU S.R.L.,
进行中（未招募）
1 期
A study to test ABI-H0731 with Entecavir to treat patients with Chronic Hepatitis BChronic Hepatitis BEUCTR2018-002042-36-GBAssembly Biosciences20
进行中（未招募）
不适用
Study of Lumacaftor Monotherapy, and Lumacaftor and Ivacaftor Combination Therapy in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR MutatioCystic FibrosisEUCTR2010-020413-90-IEVertex Pharmaceuticals Incorporated120
进行中（未招募）
1 期
Study of Lumacaftor Monotherapy, and Lumacaftor and Ivacaftor Combination Therapy in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR MutatioCystic FibrosisEUCTR2010-020413-90-GBVertex Pharmaceuticals Incorporated311